Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 13/20 | 0.67 |
| ▸ | NEK2 | P51955 | 2/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.64 |
| ▸ | CDK1 | P06493 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | CDK7 | P50613 | 2/20 | 0.64 |
| ▸ | CDK9 | P50750 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064437 | 0.88 | TLK2 (0.67) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL12727794 | 0.88 | TLK2 (0.67) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL23356452 | 0.83 | NTRK1 (0.63) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL9921923 | 0.81 | TLK2 (0.72) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL19709650 | 0.81 | TLK2 (0.68) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL5358843 | 0.80 | PDPK1 (0.77) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL11926760 | 0.78 | TLK2 (0.63) | TLK2NEK2CDK5CDK1RET | |
| SCHEMBL12056351 | 0.78 | TLK2 (0.67) | TLK2NEK2CDK5CDK1RET | |
| Su-9516 SCHEMBL1170687 | 0.78 | TLK2 (1.00) | TLK2NEK2CDK5CDK1RET | |
| Su-9516 SCHEMBL1170686 | 0.78 | TLK2 (1.00) | TLK2NEK2CDK5CDK1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | TLK2 2919/4885NEK2 2928/4885CDK5 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.